[go: up one dir, main page]

CA2160583A1 - Vaccin de type cytomegalovirus recombinant - Google Patents

Vaccin de type cytomegalovirus recombinant

Info

Publication number
CA2160583A1
CA2160583A1 CA002160583A CA2160583A CA2160583A1 CA 2160583 A1 CA2160583 A1 CA 2160583A1 CA 002160583 A CA002160583 A CA 002160583A CA 2160583 A CA2160583 A CA 2160583A CA 2160583 A1 CA2160583 A1 CA 2160583A1
Authority
CA
Canada
Prior art keywords
amino acid
fragment
ser
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002160583A
Other languages
English (en)
Inventor
Stanley A. Plotkin
Robert P. Ricciardi
Eva Gonczol
Klara Berencsi
Robert F. Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States, REPRESENTED BY SECRETARY DEPARTMENT OF HE ALTH AND HUMAN SERVICES (THE)
Wistar Institute of Anatomy and Biology
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2160583A1 publication Critical patent/CA2160583A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002160583A 1993-04-16 1994-04-15 Vaccin de type cytomegalovirus recombinant Abandoned CA2160583A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4897893A 1993-04-16 1993-04-16
US08/048,978 1993-04-16

Publications (1)

Publication Number Publication Date
CA2160583A1 true CA2160583A1 (fr) 1994-10-27

Family

ID=21957451

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002160583A Abandoned CA2160583A1 (fr) 1993-04-16 1994-04-15 Vaccin de type cytomegalovirus recombinant

Country Status (3)

Country Link
EP (1) EP0708658A4 (fr)
CA (1) CA2160583A1 (fr)
WO (1) WO1994023744A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591439A (en) * 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
WO1997040165A1 (fr) 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations
AU6150498A (en) * 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
CA2330208A1 (fr) 1998-05-29 1999-12-02 Thomas Jefferson University Compositions et methodes utilisees pour modifier des populations de cellules souches hematopoietiques chez des mammiferes
US6420545B1 (en) 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
ES2340662T3 (es) 2000-07-19 2010-06-08 Advanced Research And Technology Institute Factor de crecimiento de fibroblastos (fgf23) nuevo procedimiento para el uso.
WO2002094871A1 (fr) 2001-05-24 2002-11-28 Human Dna Technology Inc Nouvel analogue du facteur de croissance des keratinocytes-2 du follicule pileux
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2004020454A2 (fr) 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Proteines de fusion modifiees a transferrine comprenant des domaines aminotransferrine ou carboxy terminal dupliques
WO2007068784A1 (fr) 2005-12-14 2007-06-21 Licentia Ltd Nouveau facteur neurotrophique et utilisations de celui-ci
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
ES2653570T3 (es) 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Células presentadoras de antígeno artificiales novedosas y usos de las mismas
US7608433B2 (en) 2005-02-09 2009-10-27 Idexx Laboratories Method of detection of classical swine fever
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1986681A4 (fr) 2006-02-23 2010-08-04 Philadelphia Children Hospital Compositions et méthodes pour moduler une hémostase au moyen de différentes formes de facteur v activé
CA2673085C (fr) 2006-12-12 2013-10-15 Biorexis Pharmaceutical Corporation Bibliotheques de proteines hybrides de transferrine
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JP2012509670A (ja) 2008-11-21 2012-04-26 ザ チルドレンズ ホスピタル オブ フィラデルフィア 血液凝固促進剤としてのヘビ第五因子及び使用方法
CA2820706C (fr) 2010-12-03 2018-05-22 Ms Technologies, Llc Expression optimisee de molecules d'acide nucleique codant pour la resistance au glyphosate dans cellules vegetales
EP2760887B1 (fr) 2011-09-30 2024-10-23 The Children's Hospital of Philadelphia Compositions et procédés pour moduler l'homéostasie
US9783817B2 (en) 2013-03-04 2017-10-10 Arkansas State University Methods of expressing and detecting activity of expansin in plant cells
WO2014191630A2 (fr) 2013-05-28 2014-12-04 Helsingin Yliopisto Modèle animal non humain codant pour un gène manf non fonctionnel
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
BR112019025792A2 (pt) 2017-06-07 2020-07-07 Spark Therapeutics, Inc. agentes de aperfeiçoamento para transfecção de células melhoradas e/ou produção de vetor raav
WO2019152957A1 (fr) 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Lymphocytes t de type adn-récepteur antigénique chimérique pour immunothérapie
AU2021363098A1 (en) 2020-10-15 2023-05-18 F. Hoffmann-La Roche Ag Nucleic acid constructs for simultaneous gene activation
CA3197730A1 (fr) 2020-10-15 2022-04-21 F. Hoffman-La Roche Ag Constructions d'acide nucleique pour transcription de va-arn
WO2023198685A1 (fr) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Procédé de détermination de génomes d'aav
CN119256220A (zh) 2022-05-23 2025-01-03 豪夫迈·罗氏有限公司 用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
EP4532737A1 (fr) 2022-06-03 2025-04-09 F. Hoffmann-La Roche AG Procédé de production de particules d'aav recombinées
WO2024013239A1 (fr) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Procédé de production de particules de virus adéno-associé recombinant
CA3264505A1 (fr) 2022-09-12 2024-03-21 Hoffmann La Roche Procédé de séparation de particules de vaa pleines et vides
IL322001A (en) 2023-02-07 2025-09-01 Hoffmann La Roche Method for detecting antibodies to anti-AAV particles
AU2024239386A1 (en) 2023-03-21 2025-08-14 F. Hoffmann-La Roche Ag Method for the production of recombinant aav particle preparations
WO2025168663A1 (fr) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Procédé de production de particules virales adéno-associées recombinées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5124440A (en) * 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
JPH03505457A (ja) * 1988-07-01 1991-11-28 ザ・チルドレンズ・ホスピタル,インコーポレイテッド サイトメガロウイルス由来のフラグメントの抗体認識
WO1990006771A1 (fr) * 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Fragments proteolytiques obtenus a partir du complexe i de glycoproteines de cytomegalovirus humain
EP0389286B1 (fr) * 1989-03-24 1996-07-10 The Wistar Institute Of Anatomy And Biology Vaccin recombinant contre le virus cytomégalo

Also Published As

Publication number Publication date
EP0708658A1 (fr) 1996-05-01
WO1994023744A1 (fr) 1994-10-27
EP0708658A4 (fr) 1997-05-21

Similar Documents

Publication Publication Date Title
US5552143A (en) Recombinant cytomegalovirus vaccine
US5591439A (en) Recombinant cytomegalovirus vaccine
CA2160583A1 (fr) Vaccin de type cytomegalovirus recombinant
WO1994017810A1 (fr) Vaccin recombine contre le cytomegalovirus
US5242829A (en) Recombinant pseudorabies virus
CA1341435C (fr) Virus recombinant, du type variole/varicelle/vaccine, servant a immuniser contre des antigenes tumoraux
US6723695B1 (en) CTL epitopes from EBV
US6448389B1 (en) Human cytomegalovirus DNA constructs and uses therefor
US20040265325A1 (en) Human cytomegalovirus antigens expressed in MVA and methods of use
JP2001520507A (ja) 組換えポックスウイルス−サイトメガロウイルス組成物および使用
FI116851B (fi) Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
Reap et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus
US20020156251A1 (en) Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine
EP0606437B1 (fr) Vaccin d'herpesvirus vivant non excretable
CA2086740A1 (fr) Vaccin tk contre le virus herpetique equin de type 4
US5369025A (en) Recombinant fowlpox vaccine for protection against Marek's disease
CA2337965C (fr) Virus herpetique equin attenue
CA2012895C (fr) Vaccin de cytomegalovirus recombinant
AU708460B2 (en) A polynucleotide herpes virus vaccine
EP0606452B1 (fr) Vaccins vecteurs d'herpesvirus felin recombine
AU672583B2 (en) Recombinant infectious bovine rhinotracheitis virus
WO1990001546A1 (fr) Vaccin contre l'herpesvirus equin-1
US6025181A (en) Equine herpesvirus-4TK mutant
JP2003235588A (ja) Hsvの治療的処置に用いるワクチン
JP2001501101A (ja) ポリヌクレオチドヘルペスウイルスワクチン

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued